Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed its fiscal 2026 10-K annual report with the SEC on Nov 18, 2026. It reported revenue of $63M (−3.6% year over year) and net income of −$68M.
- Top risk flagged: Pfizer Paxlovid patent litigation: Federal Circuit affirmed invalidity in June 2026, Unified Patent Court invalidated European counterpart in October 2026
FY2026 key financial metrics · XBRL
- Revenue
- $63M
- −3.6% YoY
- Net income
- −$68M
- +16.7% YoY
- Operating margin
- -99.0%
- +31.6 pp YoY
- EPS (diluted)
- −$2.35
- +38.8% YoY
- ROE
- -85.1%
- +41.4 pp YoY
- Operating cash flow
- −$43M
- −120.8% YoY
Source: XBRL data from the ENANTA PHARMACEUTICALS INC (ENTA) FY2026 10-K on SEC EDGAR. USD.
ENANTA PHARMACEUTICALS INC FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core model: Chemistry-driven discovery and development of wholly owned oral small-molecule drugs for viral and immunological diseases
- New 2026 advances: Zelicapavir entered registrational Phase 2b/3 RSV testing, while EDP-978 began Phase 1 for chronic spontaneous urticaria
- Pipeline expansion: MRGPRX2 program launched, EPS-5336 selected, and IND filing targeted for fourth quarter 2027
- Financial runway: $194.5 million in cash, equivalents and marketable securities, funding operations into fiscal 2029
- Notable filing-year milestone: Acute-HCV approval expanded MAVYRET/MAVIRET to the European Union in June 2026
Management Discussion & Analysis
- Revenue $63.0M, down $2.3M YoY from $65.3M, due to lower AbbVie HCV sales
- Net loss $68.2M vs $81.9M, operating loss $62.4M vs $85.3M
- Best R&D performer: immunology $55.0M, up $11.2M; worst: virology $25.9M, down $33.9M
- Operating cash used $42.6M, financing cash provided $47.7M, liquidity $194.5M
- Outlook: funding expected into fiscal 2029; RSV trial spending expected to increase, clinical-development risk remains high
Risk Factors
- Pfizer Paxlovid patent litigation: Federal Circuit affirmed invalidity in June 2026, Unified Patent Court invalidated European counterpart in October 2026
- China supply exposure: Key API intermediates and research rely on Chinese providers vulnerable to BIOSECURE Act restrictions, tariffs, sanctions and geopolitical disruption
- AbbVie royalty concentration: 54.5% of MAVYRET/MAVIRET royalties paid to OMERS through June 30, 2032
- HCV market disruption: Gilead’s authorized generic Epclusa and Harvoni, plus discounted Medicaid pricing, threaten MAVYRET/MAVIRET royalties
- Leadership transition: CEO Jay Luly plans retirement by February 1, 2027, with successor search underway amid a one-third workforce reduction in September 2026
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.